Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 4th Preview)
-
Cell and gene therapy deals
United Therapeutics agreed to buy Thymmune Therapeutics in a $140 million upfront deal, with up to $160 million in milestones tied to clinical and regulatory progress through 2031. Thymmune’s preclinical program converts human induced pluripotent stem cells into thymic cells intended to restore T-cell function after thymic decline. The lead asset, THY-100, targets congenital athymia, a rare condition with rapid early mortality in natural history cohorts. United highlighted the platform’s potential to expand beyond athymia into immune-mediated diseases and broader transplant-tolerance and longevity applications if early proof-of-concept holds.
-
Oncology pipeline—new clinical data
Roche said new phase 3 data for divarasib support a potency and selectivity advantage versus first-generation KRAS G12C inhibitors, including competitor regimens from Amgen and Bristol Myers Squibb. The company plans to submit the phase 3 results to regulators for potential use in non-small cell lung cancer driven by KRAS G12C. If reviewed favorably, the update could reshape competition in KRAS G12C—one of the most crowded molecularly targeted oncology categories—by strengthening Roche’s positioning with a next-generation inhibitor plan.
-
CRISPR control technology
Researchers led by Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported dual small-molecule-controlled CRISPR editing systems, PRINCE and Little Prince, published in Science Translational Medicine. The approach is designed to switch genome editing on with drug inducers and keep it largely silent in their absence. The work adds to the push for controllable therapeutic genome editing by addressing a key safety and precision challenge—minimizing unintended activity between dosing windows.
-
Drug discovery AI partnerships
Insilico Medicine and Takeda expanded a drug-discovery collaboration built around AI-driven candidate selection. Insilico will use its platform to identify molecules meeting predefined scientific and early development criteria, while Takeda will advance selected candidates through clinical validation using its global development capabilities. The structure reflects a common model for pairing rapid, AI-enabled early discovery with late-stage execution and regulatory pathway expertise.
-
IND filings and early clinical starts
Brightpath Biotherapeutics submitted an IND application to the FDA to begin a phase I U.S. trial of BP-2202 for multiple myeloma. The filing is tied to NCT07667868 and marks the next step in bringing the company’s program into clinical evaluation. For investors and partners, the IND start provides an early readout pathway for safety, tolerability, and preliminary pharmacology ahead of later-stage trials.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.